ArticleJournal of thoracic disease2026
Correlations between quantitative computed tomography metrics with serum fibrosis biomarkers, pulmonary function, and mortality risk in patients with idiopathic pulmonary fibrosis: a prospective cohort study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with idiopathic pulmonary fibrosis (IPF), accurate assessment of pulmonary function is critical for evaluating disease severity and predicting prognosis. We aimed to investigate correlations among quantitative computed tomography (CT) metrics, serum fibrosis biomarkers, and pulmonary function tests, as well as examining the association between quantitative imaging metrics and patient mortality. Methods: A prospective cohort study was conducted between June 2018 and December 2022. Eligible patients with IPF and healthy adults underwent quantitative CT scanning. In addition, patients underwent serum fibrosis biomarker testing and pulmonary function testing and were followed up for 2 years to record mortality. Results: A total of 57 patients and 30 healthy adults were included in the study. Sex distribution, age, body mass index, and smoking history were comparable between patients and healthy adults; however, patients showed a statistically significant higher percentage of high-attenuation area and mean image value but a lower total lung volume than healthy adults. Among patients, quantitative imaging measurements were significantly correlated with serum fibrosis biomarkers (hyaluronic acid, type IV collagen, laminin, and type III procollagen N-terminal peptide) and pulmonary function test results (forced vital capacity, forced expiratory volume in one second, and carbon monoxide diffusing capacity). During the 2-year follow-up period, 25 (43.9%) patients died. Cox proportional hazards regression analysis showed that age and quantitative imaging metrics were associated with patient mortality. Conclusions: Quantitative CT imaging can be used to assess disease severity, activity, and mortality risk in patients with IPF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.